Overview

The prevalence of post-surgical lumbar neuropathic radiculopathy is approximately 30%. Poor response to the treatments recommended for neuropathic pain, namely antidepressants and/or gabapentinoids, requires the development of new techniques to prevent this chronic pain. Certain well-tolerated techniques, such as the administration of plasma enriched with platelets and fibrin (PRF), are increasingly used in regenerative medicine for their anti-inflammatory and analgesic properties. Thus, a periradicular intraoperative application of PRF may have an analgesic effect on the intensity of residual postsurgical neuropathic pain after disc herniation surgery.

Eligibility

Inclusion criteria:

• Patient, male or female, \>18 years old at the time of signing informed consent;
• Patient for whom a diagnosis of radiculopathy on lumbar disc herniation has been made, and for whom surgery has been scheduled in the Neurosurgery department;
• Patient affiliated to a social security health insurance scheme;
• Patient able to understand the objectives and risks of research and to give informed, dated and signed consent;
• Patient having been informed of the results of the prior medical examination;
• Women of childbearing age provided that a negative blood pregnancy test is recorded at the inclusion visit and effective contraception used throughout the study.

Exclusion criteria:

• Patient with a history of lumbar spinal surgery (multiple herniated discs, herniated disc other than lumbar);
• Patient with HIV, active cancer, HBV, HCV (verified by interview);
• Patient on long-term systemic corticosteroid therapy;
• Patient with an ASA score \> 3 during the consultation with the anesthesiologist;
• Inability to give the patient informed information (patient in an emergency or life-threatening situation, difficulties in understanding);
• Patient in exclusion period (determined by a previous or ongoing study);
• Subject under safeguard of justice;
• Subject under curatorship;
• Pregnancy;
• Breastfeeding.